Transitioning to cutaquig
Evaluating SCIg therapy versus other Ig treatment options

Home / Benefits of Transitioning to cutaquig®

You have choices for treating your primary immunodeficiency (PI).1 Foremost, is deciding which route of administration to take: subcutaneous immunoglobulin therapy (SCIg), infusing PI medication under the skin, or intravenous immunoglobulin therapy (IVIg), infusing into a vein. This decision is usually based on a number of factors including the clinical characteristics of each patient, the patient’s preferences for therapy, the designated site of care (home, hospital, infusion center), and sometimes, even insurance coverage.2

These patient-specific and lifestyle considerations may point you in one direction or the other, which you should thoroughly discuss with your healthcare provider. Because it has been demonstrated to be safe and effective,3,4 many patients today are opting for the freedom, flexibility, and convenience of SCIg.2,5

A Quick Comparison of SCIg versus IVIg

Quick Comparison
SCIg IVIg
Who
Who Infusion can be performed by patient or caregiver after training Infusion usually performed by an HCP
Where
Where Once properly trained, treatment can be administered almost anywhere (home, office, vacation, etc.)2,5 Usually performed in a healthcare facility/infusion clinic
When
When Every other week, weekly, or several times a week1,3 Usually every 3–4 weeks
Administration
Administration Subcutaneous (under the skin). Flexible administration tailored to lifestyle.3 Intravenous (into a vein). Structured administration by HCP.
Time to Infuse
Time to Infuse 5 minutes to 2 hours 2 to 6 hours
Absorption Rate
Absorption Rate Slower absorption3 Faster administration and absorption
Ig Levels
Ig Levels Steady state Ig levels3,7 Peaks and troughs in Ig levels: “wash out”7
Side Effects
Side Effects Often has very few systemic side effects3 Can have more systemic side effects such as: fever, muscle or joint pain, histamine or asthma reactions.3

Preparing for Your Transition to cutaquig

If you elect to go with cutaquig, whether you’re new to SCIg or transitioning from your current PI treatment to cutaquig, it’s important to work closely with your healthcare provider for instruction and guidance.1

Transitioning Essentials: Get Set for Success

Before transitioning to cutaquig, remember these key steps:

  • Financial Readiness: Ensure you’re covered
  • Infusion Equipment: Secure your necessary tools
  • Enroll in Recycling: Automatically recycle all infusion materials
  • Self-Administration: Get the training you need

IgCares: Your Transition Partner

Octapharma’s IgCares patient support program supports every step of your transition – helping with insurance, claims, information about co-pay assistance, on-call nurse support, full-service recycling, and even charitable giving.

Ready to start? Get all the support you need for a seamless switch to SCIg by joining IgCares. You can request a cutaquig patient Welcome Kit, containing the cutaquig Patient Handbook, infusion guide, FAQs, infusion journal, reimbursement and information reference cards, and more. And that’s just the beginning – as a member of IgCares you’ll enjoy a robust suite of features and benefits that will support your treatment journey from transition to successful ongoing treatment.

Learn more or sign up today at igcares.com.

References:
  1. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.
  2. Immune Deficiency Foundation. IDF Patient & Family Handbook for Primary Immunodeficiency Diseases FIFTH EDITION; 2013.
  3. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287,
  4. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.
  5. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference December 10, 2015. http://www.igliving.com/life-with-ig/teleconference/advantages-and-disadvantages-of-intravenous-and-subcutaneous-immune-globulin-therapy.html. Accessed April 25, 2019.
  6. Immune Deficiency Foundation. Immune Deficiency Foundation Guide to Immunoglobulin Replacement Therapy for People Living with Primary Immunodeficiency Diseases; 2018.
  7. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097